Harvard’s immune-silent stem cell technique licensed to Sana Biotechnology

Tuesday, March 26, 2019 - 00:10 in Health & Medicine

Protecting transplanted cells from immune attack is a serious challenge. As with any organ transplant, cell lines derived from stem cells are sometimes rejected. Innovations by Harvard University researchers are now enabling a new company to develop a solution that may work in cell therapies for any patient with any disease. Harvard’s Office of Technology Development (OTD) has executed a license agreement with Sana Biotechnology, a recently launched company co-founded by Harvard faculty that is focused on creating and delivering engineered cells as medicines for patients. Harvard’s foundational technology consists of methods for producing hypoimmunogenic stem cells that can be differentiated into any cell type and then transplanted into a patient without triggering immune rejection. Sana was launched in January 2019 with operations in Seattle, Cambridge, and South San Francisco. The company’s founding venture capital firms include ARCH Venture Partners, Flagship Pioneering, and F-Prime Capital. “We are excited to have placed this important...

Read the whole article on Harvard Science

More from Harvard Science

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net